Amycretin, a novel unimolecular peptide agonist of GLP-1, amylin and calcitonin receptors, has demonstrated 24% weight loss (60 mg dose) at 36 weeks in a phase 1b/2a study and offers a promising oral formulation
PMID 2899993
Common GLP-1 Injection Site Reactions Normal Reactions When starting GLP-1 medications, mild and temporary reactions at the injection site are fairly common
1 0.16 0.48
J Neurochem 18:513519 Calabrese V, Scapagnini G, Ravagna A, Fariello RG, Giuffrida Stella AM, Abraham NG (2002) Regional distribution of heme oxygenase, HSP70, and glutathione in brain: relevance for endogenous oxidant/antioxidant balance and stress tolerance
Public attitudes toward GLP-1 weight loss remain divided Weight loss medications such as GLP-1RAs have improved obesity treatment, with drugs like semaglutide and tirzepatide helping many individuals lose significant weight